Despite clearing the cardiovascular dishonor, Avandia will be voluntarily withdrawn

Avandia(rosiglitazone), a thiazolidinediones(TZD) diabetes drug, was able to avoid the issue of having cardiovascular side effects, but decided to withdraw the domestic market, though.

It seems very contrary to other TZD drugs, such as Takeda Pharmaceuticals Korea’s Actos and Chong Kun Dang’s Duvie and other complex drugs, which have been busy increasing market shares in the antidiabetic marke...